The MGH Cancer Center presented its annual MGH Award in Cancer Research on April 8 to Michael R. Stratton, MD, PhD, director of the Wellcome Trust Sanger Institute.

MGH Cancer Center awards research prize

20/May/2011

GH RESARCH AWARD: Daniel Haber, MD, PhD, director of the MGH Cancer Center, left, and Stratton

 

The MGH Cancer Center presented its annual MGH Award in Cancer Research on April 8 to Michael R. Stratton, MD, PhD, director of the Wellcome Trust Sanger Institute. Stratton’s laboratory mapped and identified the high-risk breast cancer susceptibility gene, BRCA2, and subsequently defined several moderate-risk breast cancer susceptibility genes. Under his leadership, the Sanger Cancer Genome Project identified the mutation of B-RAF as a common driver oncogene in melanoma and has characterized the genomic mutational landscape in multiple cancers.